Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience

Table 2 European LeukemiaNet response criteria to tyrosine kinase inhibitors at first line

	Optimal	Warning	Failure
Baseline	NA	High risk or CCA/Ph+, major route	NA
3 mo	BCR-ABL1 ≤ 10% and/or Ph+ ≤ 35%	BCR-ABL1 > 10% and/or Ph+ 35%-95%	Non-CHR and/or Ph+ > 95%
6 mo	BCR-ABL1 ≤ 1% and/or Ph+ 0	BCR-ABL1 1%-10% and/or Ph+ 1%-35%	BCR-ABL1 > 10% and/or Ph+ > 35%
12 mo	BCR-ABL1 ≤ 0.1%	BCR-ABL1 > 0.1%-1%	BCR-ABL1 > 1% and/or Ph+ > 0
Then, and any at time	BCR-ABL1 ≤ 0.1%	CCA/Ph- (-7 or 7q-)	Loss of CHR Loss of CCyR Confirmed loss of MMR mutations CCA/Ph+

In 2 consecutive tests, of which one with a BCR-ABL1 transcripts level ≥ 1%. This table was originally published in Baccarani et al[5]. CCA/Ph⁺: Clonal cytogenetic abnormalities in Ph-positive cells; CCA/Ph^-: Clonal cytogenetic abnormalities in Ph-negative cells; Ph: Philadelphia chromosome; CCyR: Complete cytogenetic response; MMR: Major molecular response; NA: Not applicable.